2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1503

A Systematic Screening of Comorbidities By the Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care
Abstract Number: 2075

A Unique Naturally-Occurring Regulatory T Cell Subset Associated with Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 181

A Vascular Obstacle in Ultrasound Guided Hip Joint Injection
Abstract Number: 2705

AAA-Atpase p97-HDAC6 Controlled Poly-Ubiquitin Turnover Regulates Apoptotic and Autophagy-Associated Cell Death in Arthritis
Abstract Number: 547

Abatacept Does Not Improve Subclinical Atherosclerosis Despite Good Response in Rheumatoid Arthritis: A Cohort Study
Abstract Number: 2361

Abatacept in the Treatment of Adult Dermatomyositis and Polymyositis: a Randomized, Treatment Delayed-Start Trial
Abstract Number: 563

Abatacept Plus Methotrexate Can Effectively and Safely Regain the Target of Remission Following Re-Treatment for Flares after Drug-Free Withdrawal in Patients with Early Rheumatoid Arthritis
Abstract Number: 2778

Abatacept-Treated Rheumatoid Arthritis Patients Have Better Drug-Survival Rate When Abatacept Is the First or Second Line Biologic Agent with an Excellent Overall Safety Profile: A Single Center Experience
Abstract Number: 3078

ABCG2 rs2231142 predicts Poor Response to Allopurinol in Patients with Gout
Abstract Number: 1741

Abdominal Fat Mass Assessment in Recent Onset Spondyloarthritis: Data from the DESIR Cohort
Abstract Number: 865

Abdominal Visceral Adipose Tissue Measured By Dual Energy X-Ray Absorptiometry (DXA) As a Novel Surrogate Marker of Cardiovascular Risk in Primary Necrotizing Vasculitides
Abstract Number: 1724

Abdominal X-Rays Can Reliably Detect the Majority of CT Positive Sacroiliitis in an IBD Cohort
Abstract Number: 2577

Ablation of Fc Gamma Receptors Leads to a Decreased Bone Erosion in Experimental Arthritis Not By Altering Osteoclast Numbers within the Inflamed Joint but By Inhibiting Osteoclast Activation
Abstract Number: 1985

Abnormal B-Cell Distribution Is Improved By Tocilizumab Monotherapy in Patients with Polymyalgia Rheumatica
Abstract Number: 3059

Abnormal Body Composition in Takayasu Arteritis Patients: Role of Inflammatory Cytokines and Adipokines

« Previous Page
1
…
7
8
9
10
11
…
218
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].